Oral Alzheimer's drug targeting amyloid oligomers
Raised to date
$126.3M
of $150M offered across 1 Form D filing
Alzheon, Inc. is a biotechnology company dedicated to developing innovative treatments for Alzheimer's disease. The company focuses on creating therapeutics that aim to slow or halt the progression of Alzheimer's and potentially prevent the onset of clinical symptoms.
Alzheon stands out with its commitment to an oral anti-amyloid treatment, currently the only one in Phase 3 testing, and its application of precision medicine to neurodegenerative diseases.
| Filed | Security | Sold of offered | Filing |
|---|---|---|---|
| Feb 10, 2025 | Equity | $126.3M/ $150M | Form D/A |
Alzheimer's treatment
ALZ-801/valiltramiprosate is an oral small molecule inhibitor designed to target the neurotoxic amyloid oligomers, which are believed to play a key role in the development and progression of Alzheimer's disease.
Built for
Patients with Alzheimer's disease
